

From: Johnson, Andrew (NIH/NHLBI) [E] johnsonad2@nhlbi.nih.gov
Subject: FW: Manuscript for NHLBI review
Date: December 15, 2020 at 9:41 AM
To: Sofer, Tamar tsofer@bwh.harvard.edu



External Email - Use Caution

Tamar

FYI – good to go on submission from the NHLBI Intramural approval side

Our lab created and updates a COVID-19 GWAS Summary Statistics portal. Find out more here, follow @ADJomics or the GRASP mailing list to get updates as soon as they are released:

<https://grasp.nhlbi.nih.gov/Covid19GWASResults.aspx>

Andrew D. Johnson, Ph.D. FAHA
Senior Investigator, NHLBI
Lab of Hemostasis & Platelet Biology
Head, Biomedical Informatics
NHLBI Population Sciences Branch
The Framingham Heart Study
73 Mt. Wayte Ave. Suite #2
Framingham, MA 01702
work: 508-663-4082

From: "NHLBI_EBPDOCS (NIH/NHLBI)" <nhlbi_ebpdocs@nhlbi.nih.gov>
Date: Tuesday, December 15, 2020 at 9:39 AM
To: "Walsh, Ann (NIH/NHLBI) [E]" <walshac@nhlbi.nih.gov>, "Johnson, Andrew (NIH/NHLBI) [E]" <johnsonad2@nhlbi.nih.gov>
Subject: FW: Manuscript for NHLBI review

Hello— this paper has been approved. There were no comments.

From: Johnson, Andrew (NIH/NHLBI) [E] <johnsonad2@nhlbi.nih.gov>
Sent: Friday, December 4, 2020 8:29 AM
To: NHLBI_EBPDOCS (NIH/NHLBI) <nhlbi_ebpdocs@nhlbi.nih.gov>
Cc: Walsh, Ann (NIH/NHLBI) [E] <walshac@nhlbi.nih.gov>
Subject: Manuscript for NHLBI review

Hello

Please find attached main text and Supplement for a manuscript for NHLBI review. I am the only NHLBI author

- 1) Before submitting papers for review, please have the NHLBI author(s) reply to the items below:
 - A. Verify the funding source is acknowledged, if appropriate. YES
 - B. Verify the disclaimer statement is present. ("The views expressed in this manuscript are those of the authors and do not necessarily represent the views of the

the manuscript are those of the authors and do not necessarily represent the views of the National Heart, Lung, and Blood Institute; the National Institutes of Health; or the U.S. Department of Health and Human Services.”) YES

C. Verify that there are no critical problems with the clarity of the writing. NO PROBLEMS

D. Verify that there are no critical problems with the conclusions. They are supported by the data. NO PROBLEMS

E. Verify there are no policy-related issues or anything else that would raise any red flags. NO CONCERNS

F. Verify that notification of our press office is not a priority (not newsworthy). NOT NEWSWORTHY

G. Verify that the paper is not related to a NIH Commons Fund project. If it does concern a Common Fund project, please attach documentation of NIH Office of Strategic Coordination (OSC) approval, as required on the Common Fund policy here. NOT RELATED

2) If there are supplemental docs for a paper, please consolidate them into one doc. (So there would be 2 attachments: the main paper and the supplemental information doc.) DONE

3) Which journal will this manuscript be submitted to? EUROPEAN JOURNAL OF HUMAN GENETICS

4) Kindly provide publication cost estimate---- if there will be a cost to NHLBI when published. NHLBI WILL NOT PAY ANY PAGE CHARGES AS NHLBI DIR PIS ARE NOT LEAD AUTHORS

P.S. – Ann this is a TOPMed manuscript. Not sure if it has already come to Framingham but if not it is ready to circulate there as well.

Thanks,
Andrew

Our lab created and updates a COVID-19 GWAS Summary Statistics portal. Find out more here, follow @ADJOmics or the GRASP mailing list to get updates as soon as they are released:

<https://grasp.nhlbi.nih.gov/Covid19GWASResults.aspx>

Andrew D. Johnson, Ph.D. FAHA
Senior Investigator, NHLBI
Lab of Hemostasis & Platelet Biology
Head, Biomedical Informatics
NHLBI Population Sciences Branch
The Framingham Heart Study
73 Mt. Wayte Ave. Suite #2
Framingham, MA 01702
work: 508-663-4082